These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32851922)

  • 41. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk.
    Kikuya M; Hansen TW; Thijs L; Björklund-Bodegård K; Kuznetsova T; Ohkubo T; Richart T; Torp-Pedersen C; Lind L; Ibsen H; Imai Y; Staessen JA;
    Circulation; 2007 Apr; 115(16):2145-52. PubMed ID: 17420350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register.
    Afghahi H; Svensson MK; Pirouzifard M; Eliasson B; Svensson AM
    Diabetologia; 2015 Jun; 58(6):1203-11. PubMed ID: 25773403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.
    Siddiqui M; Judd EK; Oparil S; Calhoun DA
    Hypertension; 2017 Sep; 70(3):645-651. PubMed ID: 28696223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study.
    Douros A; Tölle M; Ebert N; Gaedeke J; Huscher D; Kreutz R; Kuhlmann MK; Martus P; Mielke N; Schneider A; Schuchardt M; van der Giet M; Schaeffner E
    Eur Heart J; 2019 Jul; 40(25):2021-2028. PubMed ID: 30805599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study.
    Zhang Y; Zhang X; Liu L; Zanchetti A;
    J Hypertens; 2010 Oct; 28(10):2016-25. PubMed ID: 20625319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease.
    Agarwal R; Andersen MJ
    Am J Nephrol; 2006; 26(5):503-10. PubMed ID: 17124383
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Impact of Aortic Stiffness in Patients With Resistant Hypertension.
    Cardoso CRL; Salles GC; Salles GF
    Hypertension; 2019 Mar; 73(3):728-735. PubMed ID: 30612492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.
    Hermida RC; Ayala DE; Smolensky MH; Fernández JR; Mojón A; Portaluppi F
    Hypertens Res; 2016 May; 39(5):277-92. PubMed ID: 26657008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure.
    Zhang DY; Guo QH; An DW; Li Y; Wang JG
    J Hypertens; 2019 Sep; 37(9):1775-1785. PubMed ID: 31219948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular mortality among a cohort of hypertensive and normotensives in Rio de Janeiro - Brazil - 1991-2009.
    da Silva TL; Klein CH; Nogueira Ada R; Salis LH; de Souza E Silva NA; Bloch KV
    BMC Public Health; 2015 Jul; 15():623. PubMed ID: 26152148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension.
    Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES
    Atherosclerosis; 2011 May; 216(1):199-204. PubMed ID: 21315356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic impact of short-term ambulatory blood pressure variability for microvascular and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Salles GC; Leite NC; Salles GF
    J Hypertens; 2021 May; 39(5):935-946. PubMed ID: 33239549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):328-39. PubMed ID: 23181738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thiazide Use and Cardiovascular Events in Type 2 Diabetic Patients With Well-Controlled Blood Pressure.
    Tsujimoto T; Kajio H
    Hypertension; 2019 Dec; 74(6):1541-1550. PubMed ID: 31679424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension.
    Muxfeldt ES; Cardoso CR; Dias VB; Nascimento AC; Salles GF
    J Hypertens; 2010 Jul; 28(7):1547-53. PubMed ID: 20467326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistant hypertension: a practical clinical approach.
    Muxfeldt ES; de Souza F; Salles GF
    J Hum Hypertens; 2013 Nov; 27(11):657-62. PubMed ID: 23636008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognosis of Masked and White Coat Uncontrolled Hypertension Detected by Ambulatory Blood Pressure Monitoring in Elderly Treated Hypertensive Patients.
    Pierdomenico SD; Pierdomenico AM; Coccina F; Porreca E
    Am J Hypertens; 2017 Nov; 30(11):1106-1111. PubMed ID: 29059303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study.
    Diaz KM; Booth JN; Calhoun DA; Irvin MR; Howard G; Safford MM; Muntner P; Shimbo D
    Hypertension; 2014 Sep; 64(3):465-71. PubMed ID: 24914189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.